Shares of Reata Pharmaceuticals RETA were unchanged after the company reported Q2 results.
Quarterly Results
Earnings per share decreased 7.89% year over year to ($1.23), which beat the estimate of ($2.84).
Revenue of $3,073,000 decreased by 60.77% from the same period last year, which beat the estimate of $1,040,000.
Outlook
Earnings guidance hasn't been issued by the company for now.
Reata Pharmaceuticals hasn't issued any revenue guidance for the time being.
How To Listen To The Conference Call
Date: Aug 10, 2020
Time: 08:30 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/hr8ew88f.
Recent Stock Performance
Company's 52-week high was at $257.96
52-week low: $70.00
Price action over last quarter: down 5.64%
Company Overview
Reata Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases by targeting molecular pathways. The company's product in the pipeline include bardoxolone methyl; Omaveloxolone and others.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.